Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.

Before this study, there was concern that cetuximab could even be worse than radiotherapy alone in older adults, based on an observed trend toward worse outcomes in patients older than 65 years. 31 This, coupled with the presumption that immunotherapy would likely improve outcomes, prompted the use of a 2:1 randomisation, ostensibly to limit exposure of patients in the control group to potentially less effective therapy.

also in 242 other papers